Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1104-1111

  Iyengar, Sujatha ^a   Zhan, Caixin ^a   Lu, Jordan ^a   Korngold, Robert ^a   Schwartz, David H ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Fasudil; GVHD; Haploidentical; Intestinal tract; Rho kinase

Indexed keywords

FASUDIL; GAMMA INTERFERON; THYMOCYTE ANTIBODY; RHO KINASE;

ADULT; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DIARRHEA; DISEASE MODEL; DISEASE SEVERITY; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HAPLOIDY; HISTOPATHOLOGY; HOST CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; MOUSE MODEL; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; THYMUS; TRANSPLANTATION TOLERANCE; WEIGHT REDUCTION; ACUTE DISEASE; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PROCEDURES; SURVIVAL;

ACUTE DISEASE; ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; RHO-ASSOCIATED KINASES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84903955937     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.029     Document Type: Article

References (70)

1. Hill G.R., Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000, 95:2754-2759.
2. Chen X., Dodge J., Komorowski R., Drobyski W.R. Acritical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. Blood 2013, 121:3970-3980.
3. Takatsuka H., Iwasaki T., Okamoto T., Kakishita E. Intestinal graft-versus-host disease: mechanisms and management. Drugs 2003, 63:1-15.
4. Cho B.S., Lee S.E., Song H.H., et al. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes. Biol Blood Marrow Transplant 2012, 18:1136-1143.
5. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. NEngl J Med 2012, 367:135-145.
6. Ringdén O., Shrestha S., da Silva G.T., et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012, 47:831-837.
7. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
8. Signori A., Crocchiolo R., Oneto R., et al. Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012, 47:1474-1478.
9. Patterson A.E., Korngold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:187-196.
10. Fanning S.L., Zilberberg J., Stein J., et al. Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model. JImmunol 2013, 190:447-457.
11. Nadal E., Garin M., Kaeda J., et al. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007, 21:472-479.
12. Petrovic A., Alpdogan O., Willis L.M., et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2004, 103:1542-1547.
13. Haarberg K.M., Li J., Heinrichs J., et al. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood 2013, 122:2500-2511.
14. Penack O., Henke E., Suh D., et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. JNatl Cancer Inst 2010, 102:894-908.
15. Penack O., Socié G., van den Brink M.R. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011, 117:4181-4189.
16. Koenecke C., Prinz I., Bubke A., et al. Shift of graft-versus-host-disease target organ tropism by dietary vitamin A. PLoS One 2012, 7:e38252.
17. Palmer L.A., Sale G.E., Balogun J.I., et al. Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:311-319.
18. Murai M., Yoneyama H., Harada A., et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. JClin Invest 1999, 104:49-57.
19. Stirzaker R.A., Biswas P.S., Gupta S., et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012, 21:656-661.
20. Wang D.S., Dou K.F., Li K.Z., Song Z.S. Enhancement of migration and invasion of hepatoma cells via a rho GTPase signaling pathway. World J Gastroenterol 2004, 10:299-302.
21. Vishnubhotla R., Sun S., Huq J., et al. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest 2007, 87:1149-1158.
22. Kamai T., Tsujii T., Arai K., et al. Significant association of rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003, 9:2632-2641.
23. Sahai E., Marshall C.J. ROCK and Dia have opposing effects on adherens junctions downstream of rho. Nat Cell Biol 2002, 4:408-415.
24. Croft D.R., Sahai E., Mavria G., et al. Conditional ROCK activation invivo induces tumor cell dissemination and angiogenesis. Cancer Res 2004, 64:8994-9001.
25. Somlyo A.V., Bradshaw D., Ramos S., et al. Rho-kinase inhibitor retards migration and invivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000, 269:652-659.
26. Ying H., Biroc S.L., Li W.W., et al. The rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006, 5:2158-2164.
27. Bourguignon L.Y., Zhu H., Shao L., et al. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999, 43:269-287.
28. Barreiro O., Yanez-Mo M., Serrador J.M., et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. JCell Biol 2002, 157:1233-1245.
29. Suzuki Y., Shibuya M., Satoh S., et al. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008, 48:241-247. discussion 247-248.
30. Zhao J., Zhou D., Guo J., et al. Fasudil Aneurysmal Subarachnoid Hemorrhage Study Group. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 2011, 51:679-683.
31. Nguyen H.T., Dalmasso G., Torkvist L., et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. JClin Invest 2011, 121:1733-1747.
32. Davies J.K., Gribben J.G. Blockade of chemotaxis in graft-versus-host disease. NEngl J Med 2012, 367:1667. author reply 1667-1668.
33. Gomez A, Hammer S, Braun T, etal. A novel CD4+CD146+CCR5+ T-cell population is a biomarker of intestinal graft-versus-host disease. Presented at the 39th annual meeting of the European Group for Bloodand Marrow Transplantation, April 10, 2013, London, UK, abstract0390.
34. Morita N.I., Matsumura Y., Morita K., Miyachi Y. Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases. JDermatol 2007, 34:254-257.
35. Li Y., Harada T., Juang Y.T., et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. JImmunol 2007, 178:1938-1947.
36. Smith A., Bracke M., Leitinger B., et al. LFA-1-induced T cell migration on ICAM-1 involves regulation of MLCK-mediated attachment and ROCK-dependent detachment. JCell Sci 2003, 116(Pt 15):3123-3133.
37. Noma K., Rikitake Y., Oyama N., et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. JClin Invest 2008, 118:1632-1644.
38. Lee J.H., Katakai T., Hara T., et al. Roles of p-ERM and rho-ROCK signaling in lymphocyte polarity and uropod formation. JCell Biol 2004, 167:327-337.
39. Zhu F., Zhang Z., Wu G., et al. Rho kinase inhibitor fasudil suppresses migration and invasion through down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 2011, 28:565-571.
40. Lämmermann T., Bader B.L., Monkley S.J., et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008, 453:51-55.
41. Bardi G., Niggli V., Loetscher P. Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes. FEBS Lett 2003, 542:79-83.
42. van Buul J.D., Hordijk P.L. Signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2004, 24:824-833.
43. Li B., Zhao W.D., Tan Z.M., et al. Involvement of rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 2006, 580:4252-4260.
44. Alevriadou B.R. CAMs and rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on "VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration". Am J Physiol Cell Physiol 2003, 285:C250-C252.
45. Benais-Pont G., Punn A., Flores-Maldonado C., et al. Identification of a tight junction-associated guanine nucleotide exchange factor that activates rho and regulates paracellular permeability. JCell Biol 2003, 160:729-740.
46. Nohria A., Grunert M.E., Rikitake Y., et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006, 99:1426-1432.
47. Persidsky Y., Heilman D., Haorah J., et al. Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 2006, 107:4770-4780.
48. Yamamoto M., Ramirez S.H., Sato S., et al. Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol 2008, 172:521-533.
49. Bivalacqua T.J., Champion H.C., Usta M.F., et al. RhoA/rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004, 101:9121-9126.
50. Ming X.F., Viswambharan H., Barandier C., et al. 3Rho GTPase/rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002, 22:8467-8477.
51. Kuno M., Takai S., Matsushima-Nishiwaki R., et al. Rho-kinase inhibitors decrease TGF-beta-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Biochem Pharmacol 2009, 77:196-203.
52. Takata K., Morishige K., Takahashi T., et al. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008, 7:1551-1561.
53. Hata Y., Miura M., Nakao S., et al. Antiangiogenic properties of fasudil, a potent rho-Kinase inhibitor. Jpn J Ophthalmol 2008, 52:16-23.
54. Washida N., Wakino S., Tonozuka Y., et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant 2011, 26:2770-2779.
55. Nakabayashi H., Shimizu K. HA1077, a rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 2011, 102:393-399.
56. Clambey E.T., McNamee E.N., Westrich J.A., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012, 109:E2784-E2793.
57. Deng B., Zhu J.M., Wang Y., et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-β1 in gastric cancer. PLoS One 2013, 8:e63777.
58. Fiegl M., Samudio I., Clise-Dwyer K., et al. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009, 113:1504-1512.
59. Yan M., Jene N., Byrne D., et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011, 13:R47.
60. Facciabene A., Peng X., Hagemann I.S., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
61. Synnestvedt K., Furuta G.T., Comerford K.M., et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. JClin Invest 2002, 110:993-1002.
62. Eltzschig H.K., Köhler D., Eckle T., et al. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009, 113:224-232.
63. Corzo C.A., Condamine T., Lu L., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. JExp Med 2010, 207:2439-2453.
64. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358.
65. Beavis P.A., Stagg J., Darcy P.K., Smyth M.J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012, 33:231-237.
66. Jin D., Fan J., Wang L., et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010, 70:2245-2255.
67. Antonioli L., Blandizzi C., Pacher P., Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013, 13:842-857.
68. Procaccini C., Galgani M., De Rosa V., Matarese G. Intracellular metabolic pathways control immune tolerance. Trends Immunol 2012, 33:1-7.
69. Crecelius A.R., Kirby B.S., Richards J.C., et al. Mechanisms of ATP-mediated vasodilation in humans: modest role for nitric oxide and vasodilating prostaglandins. Am J Physiol Heart Circ Physiol 2011, 301:H1302-H1310.
70. Wu T.J., Wang Y.C., Wu T.H., et al. Inhibition of allogenic T-cell cytotoxicity by hepatic stellate cell via CD4[U+207A] CD25[U+207A] Foxp3[U+207A] regulatory T cells invitro. Transplant Proc 2012, 44:1055-1059.